// App-Quantinova.ai

178 : Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Researchers

Presenter

  • Jason Gotlib

Principal Investigators

  • Vikas Gupta

  • Ayalew Tefferi

  • Daniela Cilloni

  • Andrew W. Roberts

  • Martha Wadleigh

  • Shireen Sirhan

  • Linda M Bavisotto

  • Jun Kawashima

  • Mark Kowalski

Medical Centers

  • Jewish General Hospital, Montreal, QC, Canada

  • Medical Oncology & Royal Melbourne Hospital, Parkville, Australia,

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

  • Australia

Companies

  • YM BioSciences Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Essential thrombocythemia

  • Peripheral neuropathy

  • Polycythemia vera

  • Thrombocytopenia

  • Myelofibrosis

  • Anemia

Biomarkers

  • Janus kinase

  • Red Blood Cells

Drug/Treatment

  • Momelotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved